A clinical trial listing update involving terlipressin was recorded on August 5, 2026. The study, registered as NCT07746349 and titled "Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery," is designed to compare terlipressin against placebo in the context of fibroid surgery bleeding.
The trial's current status is listed as not yet recruiting. No phase designation is specified for this study, as it is listed as NA.
No participants have been enrolled at this stage, and no outcomes or results have been posted. The listing reflects a planned comparison between terlipressin and placebo, with the stated aim of assessing bleeding reduction during fibroid surgery, according to the registration record.
Terlipressin is an approved compound. This update pertains solely to the registration of a planned trial and does not include any efficacy or safety data at this time. Further details on trial design, eligibility, and timelines are available through the official clinical trial registry listing.
Readers interested in general background on terlipressin can consult the compound overview for additional context.